FindTrial
Sign In

A multiple center and prospective clinical study of low dose of venetoclax combined with low dose of cytarabine and homoharringtonine in the treatment of newly diagnosed acute myeloid leukemia and myelodysplastic syndrome EB-2 over 60 years old or ineligible for intensive chemotherapy

A multiple center and prospective clinical study of low dose of venetoclax combined with low dose of cytarabine and homoharringtonine in the treatment of newly diagnosed acute myeloid leukemia and myelodysplastic syndrome EB-2 over 60 years old or ineligible for intensive chemotherapy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056676
Enrollment
Unknown
Registered
2022-02-10
Start date
2022-02-15
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukemia and myelodysplastic syndrome EB-2

Interventions

Eexperimental group:low-dose veneclax combined with low-dose cytarabine and homoharringtonine

Sponsors

First Hospital of Tsinghua University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age = 18 years; 2. New diagnostic AML and MDS EB-2 meeting WHO diagnostic criteria; 3. Be able to understand and willing to sign the informed consent form for this test.

Exclusion criteria

Exclusion criteria: 1. Acute promyelocytic leukemia; 2. Combination of life-threatening or treatment-affecting complications; 3. Combined with other malignant tumors who need treatment; 4. Leukemia infiltration in the central nervous system; 5. Patients who cannot guarantee the completion of the necessary treatment plan and follow-up observation; 6. The patient has any abnormality that is not suitable for this study (determined by the investigator).

Design outcomes

Primary

MeasureTime frame
Overall response rate;Overall survival;—

Secondary

MeasureTime frame
Time to response;Relapse rate;Rates of death;—

Countries

China

Contacts

Public ContactZhenxing Guo

First Hospital of Tsinghua University

gzx2962@outlook.com+86 15001393801

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026